XML 26 R16.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Intangible assets | 9 Months Ended
--- | ---
Sep. 30, 2022
Intangible Assets [Abstract] |
Intangible assets | Intangible assets Licenses classified as definite-lived intangible assets are amortized over their useful lives, which are determined on the basis of the expected pattern of consumption of the expected future economic benefits embodied in the licenses and which therefore commence only once the necessary regulatory and marketing approval has been received for the product candidates to which they relate. The Company classifies its licenses relating to product candidates for which regulatory approval has not been received as indefinite-lived intangible assets and did not recognize amortization expense relating to these licenses. Internal development costs are classified as indefinite-lived intangible assets and are expected to be capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market. The Company began to capitalize internal development costs for ZYNLONTA as an internally generated intangible asset upon the FDA approval in the U.S. and if certain recognition criteria were met. During the nine months ended September 30, 2022, the Company capitalized the following license fees paid or accrued to third parties as intangible assets: Milestone Payments •An amount of KUSD 500 paid upon the dosing of a specific number of patients in the first in-human clinical study related to an antibody the Company acquired from a third party to be used in research, development, manufacturing and commercialization. The amount was capitalized as an indefinite-lived intangible asset; and •An amount of KUSD 195 paid upon the successful completion of in-vivo efficacy studies related to a license with a third party to use their specific binding proteins in the development, manufacturing and commercialization of products. The amount was capitalized as an indefinite-lived intangible asset. During the nine months ended September 30, 2021, the Company capitalized the following as intangible assets: Milestone Payments • An amount of KUSD 1,050 paid upon the successful completion of a pre-clinical toxicology study and IND submission related to an antibody the Company acquired from a third party to be used in research, development, manufacturing and commercialization. The amount was capitalized as an indefinite-lived intangible asset; and • An amount of KUSD 600 paid upon final regulatory approval of ZYNLONTA related to a license agreement with a third party to use their technology to research, develop, manufacture and commercialize products. The amount was capitalized as a definite-lived intangible asset and will be amortized over its estimated useful life of 14 years based on the expected patent life, which includes an extension period that the Company believes is highly probable of being granted. This estimated useful life does not include additional patent protection that may be granted under applications filed but not yet approved other than the extension period discussed above. License Payments • An amount of KUSD 400 relating to a license agreement with a third party to use their proprietary conjugation technology to research, develop, manufacture and commercialize products. The amount was capitalized as an indefinite-lived intangible asset. • An amount of KUSD 250 paid relating to a license agreement with a third party to acquire an antibody to be used in research, development, manufacturing and commercialization. The amount was capitalized as an indefinite-lived intangible asset. The table below provides a rollforward of the Company’s intangible assets as of September 30, 2022 and 2021.
(in KUSD) | Indefinite lived |  | Definite lived |  |
Cost | Licenses |  | Internal development costs |  | Licenses |  | Software |  | Total
January 1, 2022 | 12,985 |  |  | 631 |  |  | 1,052 |  |  | 176 |  |  | 14,844 |
Additions | 695 |  |  | 323 |  |  | — |  |  | 97 |  |  | 1,115 |
Exchange differences | — |  |  | — |  |  | — |  |  | (17) |  |  | (17) |
September 30, 2022 | 13,680 |  |  | 954 |  |  | 1,052 |  |  | 256 |  |  | 15,942 |
Accumulated Amortization |  |  |  |  |  |  |  |  |
January 1, 2022 | (1,069) |  |  | — |  |  | (50) |  |  | (143) |  |  | (1,262) |
Amortization charge | — |  |  | — |  |  | (56) |  |  | (32) |  |  | (88) |
Exchange differences | — |  |  |  |  | — |  |  | 6 |  |  | 6 |
September 30, 2022 | (1,069) |  |  | — |  |  | (106) |  |  | (169) |  |  | (1,344) |
Net book amount as of September 30, 2022 | 12,611 |  |  | 954 |  |  | 946 |  |  | 87 |  |  | 14,598 |
Cost |  |  |  |  |  |  |  |  |
January 1, 2021 | 11,144 |  |  | — |  |  | — |  |  | 168 |  |  | 11,312 |
Additions | 1,700 |  |  | 926 |  |  | 600 |  |  | 14 |  |  | 3,240 |
Transfers | (452) |  |  | — |  |  | 452 |  |  | (6) |  |  | (6) |
September 30, 2021 | 12,392 |  |  | 926 |  |  | 1,052 |  |  | 176 |  |  | 14,546 |
Accumulated Amortization |  |  |  |  |  |  |  |  |
January 1, 2021 | (1,069) |  |  | — |  |  | — |  |  | (64) |  |  | (1,133) |
Amortization charge | — |  |  | — |  |  | (31) |  |  | (65) |  |  | (96) |
September 30, 2021 | (1,069) |  |  | — |  |  | (31) |  |  | (130) |  |  | (1,230) |
Net book amount as of September 30, 2021 | 11,323 |  |  | 926 |  |  | 1,021 |  |  | 46 |  |  | 13,316 |

X
- Definition Intangible Assets [Abstract] + References No definition available. + Details
Name: | adc_IntangibleAssetsAbstract
Namespace Prefix: | adc_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for intangible assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2022-03-24 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS38_g118-128__IAS38_g118-128_TI -URIDate 2022-03-24 + Details
Name: | ifrs-full_DisclosureOfIntangibleAssetsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration